Scarica l'app Stockscreener
22.67
0.66%
-0.15
Dopo l'orario di chiusura:
22.67
Precedente Chiudi:
$22.82
Aprire:
$22.68
Volume 24 ore:
1.33M
Relative Volume:
0.95
Capitalizzazione di mercato:
$2.52B
Reddito:
$-665.00K
Utile/perdita netta:
$-150.11M
Rapporto P/E:
-15.04
EPS:
-1.5071
Flusso di cassa netto:
$-124.53M
1 W Prestazione:
+12.39%
1M Prestazione:
+27.57%
6M Prestazione:
+52.25%
1 anno Prestazione:
+196.73%
Intervallo 1D:
$22.00
$23.03
Intervallo di 1 settimana:
$20.32
$24.60
Portata 52W:
$7.605
$24.60
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
22.67 | 2.17B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
17.55 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.93 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.14 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.83 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.66 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | Stifel | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD - Investing.com
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Balance Sheet - TradingKey
AMLX|Amylyx Pharmaceuticals Inc|Price:18.410|Chg%:+0.820 - TradingKey
Amylyx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Chief Legal Officer & General Counsel Gina Mazzariello Sold A Bunch Of Shares In Amylyx Pharmaceuticals - 富途牛牛
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24 - Moomoo
Mizuho raises Amylyx stock price target to $24 ahead of trial data By Investing.com - Investing.com South Africa
Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com Nigeria
Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating - marketscreener.com
Lobbying Update: $40,000 of AMYLYX PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock - Sahm
Amylyx Pharmaceuticals (AMLX) Holds Steady Near $17.30 Amid Modest Downside – Key Levels in FocusETF Inflow Streak - dars.gov.et
Insider Sell: Gina Mazzariello Sells 30,000 Shares of Amylyx Pha - GuruFocus
Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan - Stock Titan
Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr
Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr
Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com
Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN) - The Globe and Mail
Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo
Amylyx Pharmaceuticals (AMLX) Edges Higher Amid Cautious Trading at $17.99Tick Index - DonanımHaber
Amylyx Pharmaceuticals Gains Attention as LUCIDITY Trial Results LoomEarnings Power Value - dars.gov.et
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amylyx Pharmaceuticals Inc Azioni (AMLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Jul 10 '26 |
Sale |
17.61 |
15,000 |
264,122 |
179,090 |
0.47%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):